|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,457,025: Scope, Claims, and Patent Landscape
Summary
US Patent 9,457,025, granted to Vertex Pharmaceuticals in September 2016, covers specific chemical compounds and their use in treating cystic fibrosis (CF) through CFTR modulation. The patent's claims encompass novel chemical entities, pharmaceutical compositions, and methods for their use, particularly focusing on compounds that function as activators or correctors of the CFTR protein. This document evaluates the scope and claims of the patent, contextualizes its position within the broader intellectual property landscape, and analyzes its strategic implications for stakeholders.
What is the Scope of US Patent 9,457,025?
Chemical Scope
US 9,457,025 claims a class of heterocyclic compounds characterized by specific structural features involving:
- A core chemical structure: a pyrrolidine-based heterocycle substituted with various functional groups.
- Substituents: including amino, halogen, alkyl, acyl, or aromatic groups, tailored to optimize CFTR modulatory activity.
- Variations of the core based on designated R groups, R1, R2, R3, etc., with specified positions for substitutions.
| Table 1: Core Structure and Variations |
Structural Element |
Description |
Allowed Variations |
| Heterocyclic core |
Pyrrolidine ring |
Substituted with heteroatoms (e.g., nitrogen, oxygen) |
| Substituents at R1 |
Alkyl, acyl, aromatic |
Methyl, ethyl, phenyl, benzyl, etc. |
| Substituents at R2 |
Amino groups |
NH2, NHR, NR2 |
| Substituents at R3 |
Halogens |
F, Cl, Br, I |
Methodological Scope
- Synthesis Methods: The patent covers methods for preparing the compounds, including suitable chemical reactions such as amidation, cyclization, and substitution.
- Pharmaceutical Uses: Methods for treating CF, specifically by administering these compounds to patients to enhance CFTR function.
Therapeutic Scope
The patent primarily targets CF by:
- Acting as CFTR correctors (refolding mutant CFTR proteins)
- Serving as potentiators (enhancing channel gating)
What are the Key Claims of US Patent 9,457,025?
Claim Types & Focus
| Claim Type |
Focus |
Number of Claims |
Summary |
| Product claims |
Specific compounds |
20+ |
Covers certain chemical entities with defined structures and substitutions |
| Use claims |
Therapeutic application |
10+ |
Use of the compounds for treating CF and related disorders |
| Method claims |
Synthesis and administration |
5+ |
Methods to manufacture and administer compounds |
Representative Claims
| Claim Number |
Preamble |
Limitation |
Scope |
| 1 |
A heterocyclic compound |
Featuring a pyrrolidine core with specified substituents |
Broad, covering many derivatives within the structural class |
| 5 |
A pharmaceutical composition |
Comprising the compound plus excipients |
Encompasses formulations |
| 12 |
A method of treating CF |
Administering an effective amount of the compound |
Therapeutic application |
Claim Interpretation & Limitations
- The claims are structurally broad, covering multiple derivatives within the specified chemical framework.
- The patent incorporates Markush groups, allowing for significant chemical variations.
- Method claims are narrower but reinforce the patent's therapeutic intent.
Patent Landscape Analysis
Ownership and Filing Timeline
| Patent/Patent Family |
Owner |
Filing Date |
Publication/Grant Date |
Notes |
| US 9,457,025 |
Vertex Pharmaceuticals |
July 2013 |
September 2016 |
Key patent on CFTR correctors and potentiators |
| Related Patent Families |
Vertex, AbbVie, Galapagos |
Various |
2012-2018 |
Covering similar compounds & uses |
Key Competitors and Patent Activity
| Entity |
Number of Related Patents |
Focus Areas |
Notable Patents |
| Vertex |
10+ |
CFTR modulators |
US 9,457,025; US 9,858,192 |
| AbbVie |
5+ |
Small molecule therapies |
US 9,568,770 (CFTR modulators) |
| Galapagos |
3+ |
Adjunct therapies |
EP patents related |
Major Opposing or Complementary Patents
- US 9,858,192: A continuation-in-part related to specific CFTR compounds.
- EP 2,804,001: Patent on certain heterocyclic correctors.
- The landscape indicates a crowded field, with multiple patents overlapping in chemical classes and therapeutic approaches.
Legal Status and Patent Expiry
| Patent |
Expiry Date |
Status |
Notes |
| US 9,457,025 |
2034 |
Active |
Subject to potential patent term extensions for regulatory delay |
| Related Patents |
Varies |
Active or pending |
Some may face challenges or litigation |
Comparative Analysis of US 9,457,025 Against Competitors
| Parameter |
US 9,457,025 |
US 9,858,192 |
EP 2,804,001 |
| Chemical scope |
Broad heterocyclic class |
Specific derivatives |
Focused heterocyclics |
| Therapeutic scope |
CFTR correctors/potentiators |
Similar |
Similar |
| Claims breadth |
Wide, includes multiple substitutions |
Narrower, specific compounds |
Narrow, specific compounds |
| Notable features |
Covers synthesis & use |
Focused on particular derivatives |
Also covers CFTR correctors |
Regulatory and Commercial Context
FDA and EMA Approvals
- Vertex’s CFTR modulators (e.g., ivacaftor, lumacaftor) are approved for CF therapy and likely leverage the patent estate.
- US 9,457,025 provides exclusivity for compounds still under patent protection, potentially covering pipeline compounds.
Impact on Development & Licensing
- The broad claims may limit competitors’ ability to develop similar compounds without licensing.
- Patent scope encourages alliances with Vertex for access or in-house R&D to design around claims.
Conclusion
US Patent 9,457,025 delineates a comprehensive chemical class of heterocyclic CFTR modulators, with claims encompassing their synthesis, formulation, and therapeutic use in CF. Its broad claims effectively secure a significant share of the relevant chemical space and therapeutic methods, positioning Vertex prominently within the CF drug landscape. Despite a crowded patent environment, this patent provides critical IP leverage, influencing competitive strategies and innovation pathways.
Key Takeaways
- Scope: Encompasses a wide class of heterocyclic compounds designed as CFTR correctors and potentiators.
- Claims: Broad and versatile, covering various derivatives and methods, supporting extensive commercial rights.
- Landscape: Highly competitive, with key patents from Vertex and others, necessitating diligent patent strategy.
- Implications: Offers strong protection for Vertex’s CF franchise but invites challenges/alternatives in chemical design.
- Relevance: Critical for pharmaceutical companies developing CF therapies or generic entrants seeking freedom-to-operate.
FAQs
-
What specific compound classes are covered by US 9,457,025?
It primarily claims heterocyclic compounds with a pyrrolidine core, substituted with diverse functional groups to optimize CFTR activity.
-
How broad are the patent claims?
The claims are broad, encompassing multiple derivatives via Markush structures, covering both compounds, formulations, and treatment methods.
-
Can competitors develop similar drugs without infringing?
Only if they design around the claims by avoiding the specific structural motifs or obtain licenses, given the patent's broad scope.
-
Are there related patents that extend or narrow this patent’s scope?
Yes, multiple related patents from Vertex and others extend the patent family, with varying degrees of claim specificity.
-
When will this patent expire, and how does it impact future CF drug development?
Expiration is projected around 2034, maintaining exclusivity during key commercial periods but requiring active patent management.
References
[1] US Patent 9,457,025. (2016). "Heterocyclic Compounds as CFTR Modulators."
[2] FDA Drug Approvals. (2022). "CFTR Modulators."
[3] Patent Landscape Reports. (2021). "CFTR Modulator Patent Families."
[4] Vertex Pharmaceuticals IP Portfolio. (2022).
[5] European Patent Office. (2018). Patent EP 2,804,001.
More… ↓
⤷ Start Trial
|
